A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition. (19th May 2020)

• Record Type: Journal Article
• Authors: Li, Xia; Junge, Lisa; Taubert, Max; von Georg, Anabelle; Dahlinger, Dominik; Starke, Chris; Frechen, Sebastian; Stelzer, Christoph; Kinzig, Martina; Sörgel, Fritz; Jaehde, Ulrich; Töx, Ulrich; Goeser, Tobias; Fuhr, Uwe
• Is Part Of: Journal of clinical pharmacology. Volume 60:Number 9(2020)
• Page Start: 1237
• Page End: 1253
• Publication Date: 2020-05-19
• Subjects: voriconazole -- midazolam -- CYP3A -- drug‐drug interaction -- semiphysiological population pharmacokinetic modeling; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.1619
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: The extent of a drug‐drug interaction (DDI) mediated by cytochrome P450 (CYP) 3A inhibitors is highly variable during a dosing interval, as it depends on the temporal course of victim and perpetrator drug concentrations at intestinal and hepatic CYP3A expression sites. Capturing the time course of inhibition is therefore difficult using standard DDI studies assessing changes in area under the curve; thus, a novel design was developed. In a 4‐period changeover pilot study, 6 healthy men received intraduodenal or intravenous infusions of the CYP3A substrate midazolam (MDZ) at a rate of 0.26 mg/h for 24 hours. This was combined with intraduodenal or intravenous infusion of the CYP3A inhibitor voriconazole (VRZ), administered at rates of 7.5 mg/h from 8 to 16 hours and of 15 mg/h from 16 to 24 hours, after starting midazolam administration. Plasma and urine concentrations of VRZ, MDZ, and its major metabolites were quantified by liquid chromatography‐tandem mass spectrometry and analyzed by semiphysiological population pharmacokinetic nonlinear mixed‐effects modeling. A model including mechanism‐based inactivation of the metabolizing enzymes (maximum inactivation rate constant kinact, 2.83 h −1 ; dissociation rate constant K I, 9.33 μM) described the pharmacokinetics of VRZ well. By introducing competitive inhibition by VRZ on primary and secondary MDZ metabolism, concentration‐time profiles, MDZ and its metabolites were captured appropriately. The model provides estimates of local concentrations of substrate and inhibitor at the major CYP3A expression sites and thus of the respective dynamic extent of inhibition. A combination of intravenous and intraduodenal infusions of inhibitors and substrates has the potential to provide a more accurate assessment of DDIs occurring in both gut wall and liver.